Skip to main content

MR-Guided High-Intensity Directional Ultrasound Ablation of Prostate Cancer

Abstract

Purpose of Review

The goal of this paper was to review the novel treatment modality of high-intensity transurethral directional ultrasound for prostate cancer.

Recent Findings

Prostate cancer is a heterogeneous disease with some patients electing for active surveillance and focal therapies instead of definitive treatment with radical prostatectomy or radiation therapy. Prostate MRI has become a cornerstone of prostate cancer diagnosis, targeted biopsy, and treatment planning. Transurethral high-intensity directional ultrasound allows for MRI-guided ablation of the prostate gland with the ability to contour boundaries and spare critical structures, such as the neurovascular bundle and urinary sphincter. Although results are still emerging, this may offer patients a new option for focal therapy with a favorable side-effect profile.

Summary

High-intensity transurethral directional ultrasound is an emerging treatment modality for both whole-gland and focal ablation with promising early results. Further research is needed to establish safety, tolerability, and long-term oncologic outcomes.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.

    PubMed  Google Scholar 

  2. 2.

    Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M, et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int. 2013;111(1):22–9. https://doi.org/10.1111/j.1464-410X.2012.11324.x.

  3. 3.

    Glaser ZA, Gordetsky JB, Bae S, Nix JW, Porter KK, Rais-Bahrami S. Evaluation of MSKCC Preprostatectomy nomogram in men who undergo MRI-targeted prostate biopsy prior to radical prostatectomy. Urol Oncol. 2019;37(12):970–5.

    Article  Google Scholar 

  4. 4.

    Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90(10):766–71.

    CAS  Article  Google Scholar 

  5. 5.

    Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–52.

    PubMed  PubMed Central  Google Scholar 

  6. 6.

    Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390–7.

    CAS  Article  Google Scholar 

  7. 7.

    Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767–77.

    Article  Google Scholar 

  8. 8.

    Gordetsky JB, Saylor B, Bae S, Nix JW, Rais-Bahrami S. Prostate cancer management choices in patients undergoing multiparametric magnetic resonance imaging/ultrasound fusion biopsy compared to systematic biopsy. Urol Oncol. 2018;36(5):241 e7–e13.

    Article  Google Scholar 

  9. 9.

    Carroll PR, Presti JC Jr, Small E, Roach M 3rd. Focal therapy for prostate cancer 1996: maximizing outcome. Urology. 1997;49(3A Suppl):84–94.

    CAS  Article  Google Scholar 

  10. 10.

    Gelet A, Chapelon JY, Margonari J, Theillere Y, Gorry F, Souchon R, et al. High-intensity focused ultrasound experimentation on human benign prostatic hypertrophy. Eur Urol. 1993;23(Suppl 1):44–7.

    Article  Google Scholar 

  11. 11.

    Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res. 1995;55(15):3346–51.

    CAS  PubMed  Google Scholar 

  12. 12.

    Beerlage HP, van Leenders GJ, Oosterhof GO, Witjes JA, Ruijter ET, van de Kaa CA, et al. High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: results of a prospective study. Prostate. 1999;39(1):41–6.

    CAS  Article  Google Scholar 

  13. 13.

    Nahar B, Bhat A, Reis IM, Soodana-Prakash N, Becerra MF, Lopategui D, et al. Prospective evaluation of focal high-intensity focused ultrasound (hifu) for patients with localized prostate cancer. J Urol. 2020;204(3):483–9. https://doi.org/10.1097/JU.0000000000001015.

  14. 14.

    Johnston MJ, Emara A, Noureldin M, Bott S, Hindley RG. Focal high-intensity focussed ultrasound partial gland ablation for the treatment of localised prostate cancer: a report of medium-term outcomes from a single-center in the United Kingdom. Urology. 2019;133:175–81.

    Article  Google Scholar 

  15. 15.

    Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D’Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177(2):540–5.

    CAS  Article  Google Scholar 

  16. 16.

    Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–74.

    Article  Google Scholar 

  17. 17.

    Huber PM, Afzal N, Arya M, Boxler S, Dudderidge T, Emberton M, et al. Prostate specific antigen criteria to diagnose failure of cancer control following focal therapy of nonmetastatic prostate cancer using high intensity focused ultrasound. J Urol. 2020;203(4):734–42.

    Article  Google Scholar 

  18. 18.

    Rosenhammer B, Niessen C, Rotzinger L, Reiss J, Schnabel MJ, Burger M, et al. Oncological outcome and value of postoperative magnetic resonance imaging after focal high-intensity focused ultrasound therapy for prostate cancer. Urol Int. 2019;103(3):270–8.

    CAS  Article  Google Scholar 

  19. 19.

    Chopra R, Colquhoun A, Burtnyk M, N’Djin WA, Kobelevskiy I, Boyes A, et al. MR imaging-controlled transurethral ultrasound therapy for conformal treatment of prostate tissue: initial feasibility in humans. Radiology. 2012;265(1):303–13.

    Article  Google Scholar 

  20. 20••.

    Chin JL, Billia M, Relle J, Roethke MC, Popeneciu IV, Kuru TH, et al. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: a prospective phase 1 clinical trial. Eur Urol. 2016;70(3):447–55 Of major importance: Initial phase 1 trial of MRI-guided transurethral ablation of the prostate for prostate cancer.

  21. 21.

    Ramsay E, Mougenot C, Staruch R, Boyes A, Kazem M, Bronskill M, et al. Evaluation of focal ablation of magnetic resonance imaging defined prostate cancer using magnetic resonance imaging controlled transurethral ultrasound therapy with prostatectomy as the reference standard. J Urol. 2017;197(1):255–61.

    Article  Google Scholar 

  22. 22.

    Bonekamp D, Wolf MB, Roethke MC, Pahernik S, Hadaschik BA, Hatiboglu G, et al. Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate. Eur Radiol. 2019;29(1):299–308.

    Article  Google Scholar 

  23. 23.

    Connor MJ, Gorin MA, Ahmed HU, Nigam R. Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI. Prostate Cancer Prostatic Dis. 2020;23(2):232–43. https://doi.org/10.1038/s41391-020-0206-6.

  24. 24.

    Preisser F, Cooperberg MR, Crook J, Feng F, Graefen M, Karakiewicz PI, et al. Intermediate-risk prostate cancer: stratification and management. Eur Urol Oncol. 2020;3:270–80.

    Article  Google Scholar 

  25. 25.

    Scheltema MJ, Tay KJ, Postema AW, de Bruin DM, Feller J, Futterer JJ, et al. Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project. World J Urol. 2017;35(5):695–701.

    CAS  Article  Google Scholar 

  26. 26.

    Thomsen FB, Roder MA, Jakobsen H, Langkilde NC, Borre M, Jakobsen EB, et al. Active surveillance versus radical prostatectomy in favorable-risk localized prostate cancer. Clin Genitourin Cancer. 2019;17(4):e814–e21.

    Article  Google Scholar 

  27. 27.

    Ingrosso G, Becherini C, Lancia A, Caini S, Ost P, Francolini G, et al. Nonsurgical salvage local therapies for radiorecurrent prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2020;3(2):183–97.

    Article  Google Scholar 

  28. 28.

    Marconi L, Stonier T, Tourinho-Barbosa R, Moore C, Ahmed HU, Cathelineau X, et al. Robot-assisted radical prostatectomy after focal therapy: oncological, functional outcomes and predictors of recurrence. Eur Urol. 2019;76(1):27–30.

    Article  Google Scholar 

  29. 29.

    Nair SM, Stern N, Dewar M, Siddiqui K, Smith E, Gomez JA, et al. Salvage open radical prostatectomy for recurrent prostate cancer following MRI-guided transurethral ultrasound ablation (TULSA) of the prostate: feasibility and efficacy. Scand J Urol. 2020;54(3):215–9. https://doi.org/10.1080/21681805.2020.1752795.

  30. 30.

    Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, et al. Prostate cancer, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2019;17(5):479–505.

    CAS  Article  Google Scholar 

  31. 31.

    Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol. 2018;199(3):683–90.

    Article  Google Scholar 

  32. 32.

    Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, et al. Impact of (68)Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single center study. J Nucl Med. 2020;61:1153–60.

    CAS  Article  Google Scholar 

  33. 33.

    Sundaram KM, Staruch R, Burtnyk M, Lane JS, Penson DF, Arora SS. Magnetic resonance imaging-guided transurethral ultrasound ablation of localized prostate cancer: preliminary experience from a single center in a prospective, multi-center, single-arm clinical trial. J Vasc Interv Radiol. 2020;31(5):740–6. https://doi.org/10.1016/j.jvir.2019.12.802.

  34. 34.

    Hatiboglu G, Popeneciu V, Bonekamp D, Burtnyk M, Staruch R, Pahernik S, et al. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: single-center evaluation of 6-month treatment safety and functional outcomes of intensified treatment parameters. World J Urol. 2020;38(2):343–50.

    CAS  Article  Google Scholar 

  35. 35••.

    Sundaram KM, Staruch R, Burtnyk M, Lane JS, Penson DF, Arora SS. MR imaging-guided transurethral ultrasound ablation of localized prostate cancer: preliminary experience from a single center in a prospective, multi-center, single-arm clinical trial. J Vasc Interv Radiol. 2020;31(5):740–6 e4 Of major importance: Initial published data from the phase 2 trial of TULSA for MRI-guided transurethral ultrasound ablation of prostate cancer.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Samuel J. Galgano.

Ethics declarations

Conflict of Interest

SJG and SRB have no relevant disclosures. VP has received an honorarium from Profound Medical for a research study. SA has received travel reimbursement from Profound Medical and research support from Profound Medical and the Radiological Society of North America.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on New Imaging Techniques

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Galgano, S.J., Planz, V.B., Arora, S. et al. MR-Guided High-Intensity Directional Ultrasound Ablation of Prostate Cancer. Curr Urol Rep 22, 3 (2021). https://doi.org/10.1007/s11934-020-01020-y

Download citation

Keywords

  • Prostate cancer
  • Focal therapy
  • High-intensity ultrasound
  • Ablation